A protein microarray, a detection method thereof, and an evaluation method thereof are provided. The protein microarray includes a carrier including a protein array block on a surface thereof and at least one protein immobilized on the protein array block. The at least one protein includes a spike protein and a nucleocapsid protein, and can bind to a first antibody in a to-be-tested sample. A method for detecting virus infection or evaluating the ability of a bioagent to block virus infection includes the steps of respectively adding blood, serum, plasma or the bioagent and a second antibody to the protein microarray and detecting an optical signal. The protein microarray can be used to detect a coronavirus and an influenza virus, and achieve the effect of quickly, sensitively, and accurately confirming whether a subject is infected by the virus.

Provided herein are compositions, methods, assays, and devices for diagnosing and treating a viral infection in a subject and/or detecting a viral nucleic acid in a sample. In one example, a sample is treated in a first chamber and via a closing or twisting operation, the sample is flowed into a second chamber, where any pathogenic nucleic acid is detected by oligonucleotides that are specific to the pathogen under test. Further, the oligonucleotides comprise are cleavage site for a restriction enzyme in the second chamber, which cleaves oligonucleotide-pathogenic nucleic acid hybrid resulting in the exposure of an enzyme that was being held by the oligonucleotide to its substrate, which generates a colorimetric and/or another visual readout (e.g., foam formation). Further, the methods, device, or kits provided herein can be used to detect SARS-CoV-2 in a saliva sample from a human subject as a rapid in home diagnostic test for COVID-19.

The present disclosure is directed to antibodies binding to and neutralizing Chikungunya virus (CHIKV) and methods for use thereof.

The present disclosure is directed to antibodies binding to and neutralizing the coronavirus designated SARS-CoV-2 and methods for use thereof.

Disclosed herein are devices and methods for the real-time detection of aeropathogens. The device includes an aerosampler having an air inlet and at least one collector tube, a microfluidic system which includes a container, piping, a micro-pump for flowing a liquid, and a viral detection chamber. The viral detection chamber has an electrode which may be equipped with functionalized biosensors, a counter electrode, an electronic detection system connectable to the electrodes of the viral detection chamber, and an embedded electronic processing system for processing data from the electronic detection system.

The invention provides a method for determining whether or not virus-neutralizing antibodies are present in a sample obtained from a subject and a respective kit therefore. The present invention further relates to an in vitro method for screening compounds for their ability to neutralize a virus.

Lateral flow immunoassay devices, systems, methods, and kits described herein identify, measure, detect, and analyze analytes of interest in a sample. The lateral flow' immunoassay devices described herein include a test strip without additional features common to traditional lateral flow7 immunoassays, such as housing, pads, or other materials that require complex manufacturing equipment and protocols. Thus, the devices, systems, methods, and kits described herein relate to simplified devices that eliminate complex and expensive manufacture equipment and methods.

The use of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) as a marker in a method for identifying a subject suffering from a disease caused by a coronavirus such as COVID-19 at risk of having or developing a severe form and/or a complication or at risk of death, in a method for assessing the severity of a disease caused by a coronavirus such as COVID-19, and in a method for monitoring a subject suffering from a disease caused by a coronavirus such as COVID-19.

The present invention relates to novel proteins that specifically bind to the spike protein or domains thereof of the severe acute respiratory syndrome corona vims 2 (SARS-Cov-2) or variants of SARS-Cov-2. The proteins of the present invention represent advanced and powerful tools, for example for the purification of the virus or a vaccine for the virus, by virtue of said binding affinity for spike protein or domains of the spike protein of SARS-Cov-2 or variants thereof. Thus, the novel proteins of the present invention are particularly advantageous because they allow precise capturing of proteins or particles comprising spike proteins, S1 domain, and/or RBD in affinity chromatography. Further, the novel proteins of the present invention can be used in medical applications caused by or related to SARS-Cov-2 or variants thereof.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the strain of coronavirus that causes coronavirus disease 2019 (COVID-19), the respiratory illness responsible for the COVID-19 pandemic. Antibodies produced from an immune response against SARS-CoV-2 infection are used to analyze prior exposure to the virus. The present invention provides methods for detecting antibodies in response to SARS-CoV-2 infection in a single multiplex immunoassay.